HomeAI · summaries
Storia in 4 fonti
Drug Trial Setbacks Raise Questions Over Novartis (NVS)’s Growth Pipeline
Novartis AG (NYSE:NVS) has suffered a major setback after its experimental drug del-desiran failed a late-stage trial for myotonic dystrophy type 1, a rare muscle-wasting disease with no approved treatments. The drug failed to show a statistically significant improvement over placebo on the trial’s primary endpoint, video hand opening time. Del-desiran was one of the key […]
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
letemps.ch
Novartis secoué en bourse après une succession d’échecs cliniques - Le Temps
Le géant pharmaceutique bâlois a reconnu mardi qu’un traitement en cours d’étude contre une maladie neuromusculaire n’avait pas atteint ses objectifs. Il s’agit du deuxième échec…
- ·
thestreet.com
Novartis stock in hot water after another key failure
The drugmaker saw its second late-stage trial miss in days, and Wall Street is now questioning its growth targets.
